中文

Chinese Journal of Nature >

2023 , Vol. 45 >Issue 6: 423 - 428

DOI: https://doi.org/10.3969/j.issn.0253-9608.2023.06.004

Brief Introduction of Nobel Prize

The mRNA technology won the 2023 Nobel Prize in Physiology or Medicine

Expand
  • ① Hangzhou CytoCan Biotech Limited Company, Hangzhou 310000, China；② Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China

Received date: 2023-10-25

  Online published: 2023-12-21

Fold

Abstract

One of the most significant obstacles that mRNA must overcome on its path to become a drug or vaccine is the immune surveillance and degradation it faces. Katalin Karikó and Drew Weissman won the 2023 Nobel Prize in Physiology or Medicine for their discovery of nucleoside base modifications, which enabled the development of effective mRNA vaccines against COVID-19. Through these specialized modifications, synthetic mRNAs can avoid the monitoring and degradation by immune cells. Of course, the success of mRNA vaccines is inseparable from the delivery system (LNP) and the quick deciphering of the genetic sequence of the virus. Beyond vaccines preventing pathogen infections, mRNA technology also holds a broad prospect in fields like cancer vaccines, gene editing, and cell therapy.

Cite this article

XU Yao, LI Kexin, ZHAO Lianmei, ZHANG Hongtao . The mRNA technology won the 2023 Nobel Prize in Physiology or Medicine[J]. Chinese Journal of Nature, 2023 , 45(6) : 423 -428 . DOI: 10.3969/j.issn.0253-9608.2023.06.004

References

[1] BRENNER S, JACOB F, MESELSON M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis

[J]. Nature, 1961, 190: 576-581.

[2] WATANABE K, YOKOBORI S. Genetic code: introduction [EB/OL]. (2011-10-17)[2023-10-25]. https://onlinelibrary.wiley.com/
doi/10.1002/9780470015902.a0000809.pub2.
[3] MELTON D A, KRIEG P A, REBAGLIATI M R, et al. Efficient in vitro synthesis of biologically active RNA and RNA hybridization
probes from plasmids containing a bacteriophage SP6 promoter [J].Nucleic Acids Res, 1984, 12(18): 7035-7056.
[4] KARIKÓ K, BUCKSTEIN M, NI H, et al. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA [J]. Immunity, 2005, 23(2): 165-175.
[5] KARIKÓ K, KUO A, BARNATHAN E S, et al. Phosphateenhanced transfection of cationic lipid-complexed mRNA and plasmid DNA [J]. Biochim Biophys Acta, 1998, 1369(2): 320-334.
[6] ROJAS L A, SETHNA Z, SOARES K C, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer [J].
Nature, 2023, 618(7963): 144-150.
[7] MACKENSEN A, HAANEN J B A G, KOENECKE C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in
relapsed or refractory solid tumors: the phase 1 BNT211-01 trial [J]. Nat Med, 2023, 29(11): 2844-2853.
[8] QIU M, GLASS Z, CHEN J, et al. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liverspecific
in vivo genome editing of Angptl3 [J]. Proc Natl Acad Sci USA, 2021, 118(10): e2020401118.
[9] RURIK J G, TOMBÁCZ I, YADEGARI A, et al. CAR T cells produced in vivo to treat cardiac injury [J]. Science, 2022, 375(6576): 91-96.
[10] CHENG Q, WEI T, FARBIAK L, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and
CRISPR–Cas gene editing [J]. Nat Nanotechnol, 2020, 15(4): 313-320.
[11] DOLGIN E. The tangled history of mRNA vaccines [J]. Nature, 2021, 597: 318-324.

Options
Outlines

/

〈 〉